TTY Biopharm (4105) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 東洋

TTY Biopharm (4105) reported revenue of NT$727.8 million for Oct 2026, +36.5% year on year and -20.2% from the previous month. Revenue for Jan–Oct 2026 was NT$5.87 billion (+10.3% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 11 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$634.9 million24/10Nov 2024 NT$455.2 millionDec 2024 NT$622 millionJan 2025 NT$483 millionFeb 2025 NT$409 million25/02Mar 2025 NT$567 millionApr 2025 NT$439.4 millionMay 2025 NT$537.7 millionJun 2025 NT$535.3 million25/06Jul 2025 NT$482.6 millionAug 2025 NT$457.9 millionSep 2025 NT$879.5 millionOct 2025 NT$533.3 million25/10Nov 2025 NT$487.3 millionDec 2025 NT$641.5 millionJan 2026 NT$561.1 millionFeb 2026 NT$359.6 million26/02Mar 2026 NT$599.7 millionApr 2026 NT$518.2 millionMay 2026 NT$518.4 millionJun 2026 NT$617.1 million26/06Jul 2026 NT$537 millionAug 2026 NT$525.9 millionSep 2026 NT$911.4 millionOct 2026 NT$727.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$727.8 million+36.5%-20.2%
Sep 2026NT$911.4 million+3.6%+73.3%
Aug 2026NT$525.9 million+14.9%-2.1%
Jul 2026NT$537 million+11.3%-13.0%
Jun 2026NT$617.1 million+15.3%+19.1%
May 2026NT$518.4 million-3.6%+0.0%
Apr 2026NT$518.2 million+17.9%-13.6%
Mar 2026NT$599.7 million+5.8%+66.8%
Feb 2026NT$359.6 million-12.1%-35.9%
Jan 2026NT$561.1 million+16.2%-12.5%
Dec 2025NT$641.5 million+3.1%+31.7%
Nov 2025NT$487.3 million+7.0%-8.6%
Oct 2025NT$533.3 million-16.0%-39.4%
Sep 2025NT$879.5 million+45.1%+92.1%
Aug 2025NT$457.9 million+3.2%-5.1%
Jul 2025NT$482.6 million-0.2%-9.8%
Jun 2025NT$535.3 million+13.0%-0.4%
May 2025NT$537.7 million+21.0%+22.4%
Apr 2025NT$439.4 million-3.8%-22.5%
Mar 2025NT$567 million+42.6%+38.6%
Feb 2025NT$409 million+49.0%-15.3%
Jan 2025NT$483 million-19.7%-22.3%
Dec 2024NT$622 million+22.4%+36.6%
Nov 2024NT$455.2 million-6.5%-28.3%
Oct 2024NT$634.9 million-2.2%+4.8%

Jan–Oct 2026 cumulative: NT$5.87 billion (+10.3% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: TTY Biopharm vs PEC / TTY Biopharm vs Lotus Pharm / TTY Biopharm vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16